Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice-Reference-Cited by-同舟云学术

Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice

Published:2021-06 Issue:3 Volume:21 Page:191-198
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Chen Xuelian,Wang Jiayu,Fan Ying,Luo Yang,Zhang Pin,Li Qing,Ma Fei,Yuan Peng,Chen Shanshan,Li Qiao,Cai Ruigang,Xu Binghe^ORCID

Funder

Chinese Academy of Medical Sciences Initiative for Innovative Medicine

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

2. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer;Harris;Clin Cancer Res,2007

3. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule;Baselga;J Clin Oncol,2005

4. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer;Vogel;J Clin Oncol,2002

5. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses;Cameron;Breast Cancer Res Treat,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New treatment options for HER2-positive metastatic breast cancer with leptomeningeal metastases;Meditsinskiy sovet = Medical Council;2024-07-24

2. Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors;Chinese Journal of Cancer Research;2024

3. Genomic Alterations Correlated to Trastuzumab Resistance and Clinical Outcomes in HER2+/HR- Breast Cancers of Patients Living in Northwestern China;Journal of Cancer;2024

4. Albumin-bilirubin score predicts trastuzumab resistance in HER2-positive breast cancer;Cancer Biomarkers;2023-12-15

5. Apatinib combined with trastuzumab and albumin‑bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti‑HER2 TKIs: A case report;Oncology Letters;2022-12-20